List of Excipients in Branded Drug MICRO-K EXTENCAPS

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Ther-Rx Corporation	MICRO-K EXTENCAPS	potassium chloride	64011-010	ETHYLCELLULOSE
Ther-Rx Corporation	MICRO-K EXTENCAPS	potassium chloride	64011-010	FD&C BLUE NO. 2
Ther-Rx Corporation	MICRO-K EXTENCAPS	potassium chloride	64011-010	FD&C RED NO. 40
Ther-Rx Corporation	MICRO-K EXTENCAPS	potassium chloride	64011-010	FD&C YELLOW NO. 6

MICRO-K EXTENCAPS Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

MICRO-K EXTENCAPS is an extended-release, microencapsulated potassium chloride capsule used to prevent or treat potassium depletion. Its commercial value is tied less to active-ingredient exclusivity than to formulation execution: controlled release, gastrointestinal tolerability, capsule integrity, dose flexibility, and reliable supply. The strongest opportunities are excipient modernization, dye- and allergen-reduced versions, alternative capsule shells, multiparticulate delivery, and generic or private-label distribution.

What is MICRO-K EXTENCAPS?

MICRO-K EXTENCAPS contains potassium chloride in a microencapsulated extended-release dosage form. The product is supplied in potassium-equivalent strengths, including 8 mEq and 10 mEq capsules in U.S. labeling and commercial references. The capsule is intended to release potassium chloride gradually rather than expose the gastrointestinal tract to an immediate concentrated dose.

The product is used for patients with hypokalemia or those receiving therapies that cause potassium loss. The prescribing information warns that potassium chloride products can cause gastrointestinal injury, hyperkalemia, and clinically significant drug interactions. Patients are generally instructed to take the capsules with meals and water and not to crush or chew them because disruption can affect release characteristics. [1]

Key product characteristics

Attribute	MICRO-K EXTENCAPS profile
Active ingredient	Potassium chloride
Dosage form	Extended-release capsule
Release technology	Microencapsulated potassium chloride
Strengths	Commonly referenced as 8 mEq and 10 mEq
Administration	Oral, generally with meals and water
Release constraint	Capsule should not be crushed or chewed
Main clinical use	Prevention or treatment of potassium depletion
Primary commercial competitors	Klor-Con M, K-Dur, generic potassium chloride ER tablets and capsules
Regulatory pathway	Legacy FDA-approved prescription product and generic-equivalent market
Core differentiation	Multiparticulate or microencapsulated delivery rather than a conventional immediate-release solid

Which excipients are used in MICRO-K EXTENCAPS?

The product’s inactive ingredients support bead formation, release control, capsule manufacture, color identification, and physical stability. Public labeling for potassium chloride extended-release capsules identifies excipient classes such as gelatin, sugar-based pellet components, povidone, talc, magnesium stearate, titanium dioxide, colorants, and other manufacturing aids, although the precise list can vary by strength, manufacturer, and product version. [1]

The excipient architecture likely performs several functions:

Excipient function	Typical excipient role in the product
Pellet carrier	Sucrose or starch-based cores provide a substrate for drug layering
Binder	Povidone supports adhesion of potassium chloride to pellet cores
Release modifier	Ethylcellulose, waxy materials, polymer coatings, or related barriers can slow dissolution
Lubrication	Magnesium stearate supports capsule and filling operations
Glidancy and processing	Talc or colloidal silicon dioxide can improve powder flow
Capsule shell	Gelatin provides the hard capsule structure
Opacity and appearance	Titanium dioxide and approved colorants support identification
Fill protection	Sugar, polymer, or mineral coating systems can reduce direct mucosal exposure

The commercial importance of these excipients is high because potassium chloride is highly water soluble. A poorly controlled formulation can release potassium rapidly, increasing gastrointestinal irritation and undermining the product’s extended-release profile.

How should an excipient strategy be designed for MICRO-K EXTENCAPS?

A competitive excipient strategy should protect four critical quality attributes: dissolution profile, potassium content uniformity, capsule fill-weight consistency, and gastrointestinal tolerability.

Preserve multiparticulate release control

The primary technical barrier is not the identity of the excipients. It is the reproducible construction of drug-loaded particles with a controlled coating or matrix. Development work should focus on:

• Particle-size distribution of the drug-layered pellets.
• Coating weight gain and coating uniformity.
• Mechanical resistance during capsule filling and transport.
• Moisture sensitivity of the coating system.
• Dissolution under sequential pH conditions.
• Resistance to dose dumping after mechanical agitation.
• Stability under high temperature and humidity.
• Consistency between pilot, exhibit, and commercial batches.

A generic manufacturer that changes the coating polymer, pellet core, binder, or lubricant should expect meaningful comparative dissolution and stability work. Even apparently minor excipient changes can affect release because potassium chloride dissolves readily once exposed to aqueous media.

Reduce excipient-related market friction

The most commercially useful changes are likely to be those that address patient and pharmacy concerns without changing the core release mechanism.

Potential modifications include:

1. A dye-free capsule version for patients with colorant sensitivities.
2. A gelatin-free shell using hypromellose or another accepted capsule material.
3. A lactose-free formulation if lactose is present in a target product version.
4. Reduced sugar or sugar-free pellet carriers.
5. Lower-talc or talc-free processing systems.
6. Improved moisture-barrier packaging.
7. A smaller capsule or higher-strength presentation to reduce pill burden.
8. A capsule compatible with automated pharmacy dispensing and unit-dose packaging.

These changes require regulatory assessment because inactive ingredients can influence dissolution, bioequivalence, stability, and labeling. A new formulation may be suitable for an ANDA, a supplemental application, or a separate product strategy depending on the extent of the change and the reference product used.

What formulation patents protect MICRO-K EXTENCAPS?

MICRO-K EXTENCAPS is based on an old potassium chloride extended-release concept. The principal commercial opportunity is therefore unlikely to depend on blocking patents covering the original product. The relevant intellectual-property value is more likely to reside in later patents covering:

• Specific pellet-coating compositions.
• Narrow dissolution profiles.
• Capsule shell compositions.
• Manufacturing processes for drug-layered particles.
• Methods for reducing gastrointestinal irritation.
• Sprinkle or alternative administration formats.
• High-strength or low-volume potassium chloride dosage forms.
• Packaging systems that improve moisture stability.

FDA’s Orange Book is the principal source for identifying patents and regulatory exclusivity associated with approved prescription products. Legacy potassium chloride products generally have limited or no remaining composition-of-matter protection. Patent exposure should be evaluated product by product because a generic competitor may face listed formulation or method-of-use patents even when the active ingredient itself is old. [2]

Are there current Orange Book patents for MICRO-K EXTENCAPS?

The commercial risk profile is consistent with a mature product rather than a patent-protected innovative drug. There is no widely recognized active-ingredient patent barrier for potassium chloride. Any current Orange Book risk would arise from product-specific listings, not from potassium chloride as a molecule.

For business planning, the relevant conclusion is:

IP category	Expected relevance
Potassium chloride composition patent	Negligible for a legacy product
Original extended-release concept	Likely expired or commercially weak
Microencapsulation process	Potentially relevant if a live patent is listed
Method-of-use patents	Limited practical barrier for a replacement-electrolyte product
Formulation patents	Possible, but must be verified against the current reference product
Trade secrets	Potentially important for coating process and scale-up
Regulatory exclusivity	Unlikely to be a meaningful barrier for a mature product

When does MICRO-K EXTENCAPS lose exclusivity?

MICRO-K EXTENCAPS has the profile of a mature prescription product with no meaningful remaining new-drug exclusivity based on the age of the product and the availability of generic potassium chloride extended-release products. The commercial window is therefore determined by ANDA approval, manufacturing capacity, supply reliability, state substitution rules, payer preference, and pharmacy contracting.

The practical exclusivity timeline is:

Event	Commercial implication
Original FDA approval	Established the reference product
Expiration of original patent rights	Opened generic development
Generic ANDA approvals	Reduced branded price and market share
Multiple generic suppliers	Increased price competition
Current market	Differentiation depends on formulation, supply, packaging, and distribution

No meaningful 180-day first-filer opportunity should be assumed without identifying a current, unexpired Paragraph IV certification and the relevant first applicant. The market is too mature to support an automatic assumption that a newly developed formulation has exclusivity.

Which companies are challenging MICRO-K EXTENCAPS?

The relevant challengers are manufacturers of potassium chloride extended-release tablets, capsules, and alternative oral products rather than companies developing a novel active ingredient.

Competitive products include:

• Generic potassium chloride extended-release capsules.
• Klor-Con M potassium chloride extended-release tablets.
• K-Dur and related potassium chloride extended-release tablets.
• Potassium chloride oral solutions and liquids.
• Hospital and specialty pharmacy electrolyte products.
• Nonprescription dietary potassium products, although these are not direct therapeutic substitutes in regulated prescribing.

The main competitive distinction is dosage form. Tablets may have stronger pharmacy availability and lower manufacturing cost. Capsules can offer a differentiated multiparticulate design, but they must justify their price through tolerability, swallowing characteristics, dose flexibility, or supply performance.

What Paragraph IV challenges affect MICRO-K EXTENCAPS?

Paragraph IV litigation is a certification-based challenge to a listed patent in an ANDA. For a legacy potassium chloride capsule, Paragraph IV exposure is likely to be limited unless the reference product has an active formulation or manufacturing patent listed in the Orange Book.

The principal litigation questions are:

1. Whether any patent is currently listed for the reference product.
2. Whether the patent covers the capsule, pellets, coating, or manufacturing method.
3. Whether an ANDA applicant filed a Paragraph IV certification.
4. Whether the reference sponsor sued within 45 days.
5. Whether a 30-month stay applies.
6. Whether the parties settled before trial.
7. Whether the generic product can launch at risk.

A commercial diligence review should distinguish between a true Paragraph IV challenge and a Paragraph III certification stating that a patent will be respected until expiration. They have different timing and litigation consequences. FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations and court records provide the core sources for this analysis. [2,3]

What formulation opportunities exist for MICRO-K EXTENCAPS?

Dye-free and gelatin-free capsules

A dye-free version could address pharmacy substitution and patient preference. A hypromellose capsule could expand use among patients avoiding animal-derived gelatin. These changes can create a differentiated product without changing the therapeutic category.

The main technical issues are capsule moisture behavior, shell brittleness, oxygen transmission, and compatibility with the pellet coating. Hypromellose capsules can perform differently from gelatin capsules during filling and storage.

Sprinkle or opened-capsule formats

A sprinkle product could serve patients with dysphagia or those unable to swallow conventional capsules. This opportunity carries a major regulatory constraint: the product must retain extended-release performance when administered with an approved soft food or liquid vehicle.

The label cannot casually authorize opening the capsule. The manufacturer would need to establish that the pellets remain intact, are not chewed, and do not produce rapid potassium release. A sprinkle indication could materially expand the addressable population but would require substantial formulation and clinical-use support.

Higher-strength capsules

Higher-strength presentations could reduce pill burden for patients requiring chronic supplementation. The formulation must maintain acceptable fill volume, content uniformity, dissolution, and capsule size. The commercial advantage is strongest in chronic users taking multiple capsules daily.

Pediatric and geriatric positioning

Pediatric development would require attention to dosing flexibility, administration with food, palatability, and the risk of accidental overdose. Geriatric positioning would focus on swallowability, capsule size, and medication burden. These populations are commercially relevant but require careful labeling and safety substantiation.

Packaging and supply-chain optimization

Potassium chloride products should be evaluated for moisture migration, pellet agglomeration, capsule deformation, and dissolution drift. Blister packaging, high-barrier bottles, desiccant systems, and unit-dose packaging can reduce quality complaints and improve institutional use.

Packaging can also support a private-label strategy. A manufacturer with dependable supply can sell the same formulation through retail pharmacy, mail order, hospital, and specialty-distributor channels with differentiated pack sizes.

How strong is the patent estate for MICRO-K EXTENCAPS?

The patent estate is likely weak as a blocking estate and stronger as a formulation know-how estate.

Estate component	Assessment
Active ingredient	Very weak protection because potassium chloride is an established compound
Core therapeutic use	Weak protection
Extended-release formulation	Potentially protectable, but original rights are likely old
Manufacturing process	Moderate trade-secret value
New capsule shell or sprinkle format	Potentially patentable if technically differentiated
Dissolution control	Patentable only with meaningful composition or performance distinction
Packaging	Usually narrow and commercially vulnerable
Regulatory exclusivity	Low expected value for the legacy product

A new applicant should prioritize process robustness and differentiated product claims over attempts to recreate broad, expired claims. The most defensible new intellectual property would likely cover a specific coating composition, particle architecture, dissolution behavior, or administration method supported by comparative data.

What FDA regulatory status applies to MICRO-K EXTENCAPS?

MICRO-K EXTENCAPS is an FDA-regulated prescription potassium chloride product. Its regulatory value comes from the approved dosage form and reference-product status, not from novel-drug exclusivity.

Potential regulatory routes include:

• ANDA approval for a therapeutically equivalent generic.
• Supplemental approval for certain formulation, strength, packaging, or manufacturing changes.
• NDA-based development for a materially differentiated product.
• 505(b)(2) development for a new dosage form, administration method, or clinical use that relies partly on existing data.

The appropriate route depends on whether the proposed product can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. A sprinkle formulation, novel capsule shell, different release technology, or new patient population could move the program beyond a straightforward ANDA strategy.

What commercial opportunities exist for MICRO-K EXTENCAPS?

The highest-probability opportunities are in cost-efficient generic supply and targeted differentiation.

Generic and authorized-generic supply

A manufacturer can compete through:

• Reliable API procurement.
• Multi-site manufacturing.
• Competitive acquisition cost.
• Consistent dissolution performance.
• Direct contracting with wholesalers and health systems.
• Private-label supply.
• Back-up capacity for shortage mitigation.

Potassium chloride products have a low unit price but recurring chronic demand. Gross-margin performance depends heavily on manufacturing yield, packaging cost, freight, and contract structure.

Premium differentiated products

A premium strategy would require a visible patient or pharmacy benefit. The strongest claims are likely to be:

• Dye-free.
• Gelatin-free.
• Smaller capsule.
• Higher strength.
• Sprinkle-compatible.
• Improved moisture stability.
• Unit-dose institutional packaging.
• Reduced pill burden.

A premium price without a clear administration or supply advantage is unlikely to withstand generic competition.

Licensing opportunities

Potential licensing targets include:

• A validated microencapsulation or coating process.
• A non-gelatin capsule platform.
• A high-load potassium chloride pellet system.
• A sprinkle-compatible multiparticulate technology.
• A contract manufacturer with approved potassium chloride capacity.
• A distributor seeking a private-label extended-release electrolyte product.

The most practical deal structures would be supply agreements, technology licenses, co-development arrangements, or regional commercialization rights. Royalty economics are likely to be modest unless the licensed technology solves a specific manufacturing or administration problem.

What generic launch risks exist?

Generic launch risk is primarily operational and regulatory.

Risk	Commercial consequence
Failure to match dissolution	ANDA deficiency, delay, or therapeutic-equivalence concern
Pellet breakage	Potential dose dumping and product complaints
Inconsistent coating	Batch failures and recall exposure
Capsule shell incompatibility	Stability or fill-weight problems
Potassium chloride supply disruption	Lost contracts and shortage scrutiny
Price erosion	Reduced margins after additional ANDA approvals
Label mismatch	Substitution and pharmacy barriers
Manufacturing transfer failure	Delayed launch or unstable supply
High-strength dose errors	Medication-safety exposure

The most credible launch scenario is a low-cost generic with strong supply performance. The most attractive differentiated scenario is an administration-friendly capsule supported by a defensible multiparticulate process and a clear label benefit.

How does MICRO-K EXTENCAPS compare with competing potassium chloride products?

Product type	Main advantage	Main limitation	Commercial position
MICRO-K EXTENCAPS	Microencapsulated capsule; differentiated release architecture	Capsule swallowing and possible higher cost	Niche or premium generic
Klor-Con M tablet	Broad recognition and established distribution	Tablet size and swallowing burden	Strong branded and generic competition
Generic ER tablet	Low acquisition cost	Less differentiated patient experience	Price-driven volume product
Generic ER capsule	Comparable form factor and substitution potential	Limited brand differentiation	Direct competitor
Oral solution	Flexible dosing and useful for selected patients	Taste, administration burden, measuring errors	Pediatric or special-population niche
Immediate-release potassium products	Rapid administration in selected settings	Greater GI tolerability concerns	Limited chronic-use advantage

Key Takeaways

• MICRO-K EXTENCAPS is a mature potassium chloride extended-release capsule, not a molecule protected by meaningful active-ingredient exclusivity.
• The core commercial asset is microencapsulated release technology and its manufacturing reproducibility.
• Excipient strategy should prioritize dissolution control, gastrointestinal tolerability, capsule compatibility, and moisture stability.
• Dye-free, gelatin-free, higher-strength, smaller-capsule, and sprinkle-compatible versions offer the clearest differentiation paths.
• Generic competition is likely to focus on price, supply reliability, and therapeutic equivalence.
• Paragraph IV and Orange Book risk should be assessed against current product-specific listings rather than assumed from potassium chloride’s historical patent record.
• The strongest new IP opportunity is a narrowly defined formulation or manufacturing patent supported by comparative dissolution and stability data.
• Commercial returns are more likely to come from reliable generic supply, private-label distribution, or targeted formulation improvement than from traditional brand exclusivity.

FAQs

Is MICRO-K EXTENCAPS the same as Klor-Con M?

No. Both products provide extended-release potassium chloride, but they use different dosage forms and formulation technologies. MICRO-K EXTENCAPS is a capsule containing microencapsulated material, while Klor-Con M is generally associated with an extended-release tablet platform.

Can MICRO-K EXTENCAPS capsules be opened and sprinkled on food?

The product should not be assumed to be sprinkle-compatible unless the approved labeling expressly permits opening and administration with food. Altering the capsule can change release performance and may increase gastrointestinal exposure.

Is potassium chloride a good target for a 505(b)(2) product?

It can be, but the opportunity requires a meaningful difference from existing products. A new administration route, clinically supported sprinkle formulation, substantially improved dosing flexibility, or distinct patient population could support a 505(b)(2) rationale. A minor excipient change alone would more likely fit a generic or supplemental strategy.

What is the main manufacturing challenge for a generic MICRO-K EXTENCAPS product?

The main challenge is maintaining uniform controlled release from potassium chloride-loaded particles. Coating variability, pellet damage, moisture exposure, and scale-up differences can affect dissolution and product performance.

Can a new excipient create patent protection for MICRO-K EXTENCAPS?

An excipient alone usually provides limited protection. Stronger patent claims require a defined composition, manufacturing process, dissolution result, stability benefit, or clinical-use advantage that is novel and non-obvious.

References

1. DailyMed. (n.d.). Potassium chloride extended-release capsules: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2018). ANDA submissions: Refuse-to-receive standards. FDA Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA Center for Drug Evaluation and Research.